Drug Type Antibody |
Synonyms ML-IM-05 |
Target |
Action modulators |
Mechanism LANCL2 modulators(LanC like 2 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | China | 30 Nov 2022 |






